Petros Pharmaceuticals Inc
For the period ended Mar 31, 2025. Filed May 15, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 15, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
On May 12, 2025, the Board (i) increased the annual base salary for Fady Boctor, the Company’s President and Chief Commercial Officer, from $280,000 to $350,000, less all applicable withholdings and deductions, effective June 1, 2025. In addition, on May 12, 2025, in consideration of the work done in connection with the Company’s recent financings and planned corporate restructuring, the Board approved special bonuses to certain directors and officer of the Company, including Mr. Boctor and Mitchell Arnold, the Company’s Vice President of Finance and Chief Accounting Officer, in the amount of $50,000 and $25,000, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.